Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSTART: Tirabrutinib vs Radiotherapy for Refractory Primary CNS Lymphoma
jRCT1031250645Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tirabrutinib in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Japan Clinical Oncology Group. Primary endpoints: Phase II: 4-week tirabrutinib continuation without disease progression and Phase III: Overall survival. Started Jan 2026; status: recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT1031250645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250645.